Elicio Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Elicio is a clinical-stage biotechnology company developing immunotherapies. Its lead candidate, ELI-002, is in Phase 2 clinical development; ELI-007 and ELI-008 are preclinical. The company has no approved products and reported no revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Research and development expense | $7.6 million | $5.5 million; up 38%, primarily reflecting ELI-002 clinical trial costs |
| General and administrative expense | $2.7 million | $2.3 million; up 16%, primarily personnel and public-company costs |
| Total operating expenses | $10.2 million | $7.8 million; up 31% |
| Net loss | $11.8 million | $8.0 million |
| Net loss per share, basic and diluted | $1.15 | $24.77 |
| Cash used in operating activities | $12.1 million | $8.1 million |
The per-share loss comparison is affected by a substantially different weighted-average share count (10.27 million in Q1 2024 versus 324,106 in Q1 2023) following the 2023 reverse merger and recapitalization. Gross profit and margins are not applicable to the reported period because the company had no product revenue.
At March 31, 2024, cash and cash equivalents were $11.9 million; restricted cash was $1.4 million. Current assets were $14.1 million, current liabilities $6.0 million, total assets $24.5 million, and total liabilities $19.6 million. Accumulated deficit was $154.0 million. The balance sheet included $7.9 million of warrant liabilities and $6.7 million of operating lease liabilities; the filing reports no conventional borrowings outstanding at quarter-end.
Financing activities provided $11.0 million: $5.1 million net proceeds from the at-the-market offering and approximately $6.0 million gross proceeds from a private placement of pre-funded warrants. Cash and cash equivalents declined from $12.9 million at December 31, 2023 to $11.9 million at March 31, 2024. Warrant accounting also affected results: the company recorded a $1.3 million fair-value loss and a $0.6 million loss on issuance of the pre-funded warrants.
Changes, outlook, and risks
- Operating expenses and operating cash use increased year over year as Elicio advanced ELI-002; management expects research and development and general and administrative expenses to rise as programs advance.
- Management estimates existing cash will fund planned operations into the third quarter of 2024. The filing states that additional financing is needed to fund operations for at least twelve months after issuance of the statements and that substantial doubt exists about the company’s ability to continue as a going concern.
- Potential funding sources include equity or debt financing, licensing, partnerships, collaborations, or other strategic transactions; availability and terms are uncertain. Failure to raise capital could require spending reductions, delayed or terminated development, or other scaling back of operations, and additional equity could dilute shareholders.
- The March 2024 pre-funded warrants were issued to GKCC, LLC, an entity controlled by a company director. They are exercisable at $0.01 per share, subject to a 19.99% beneficial-ownership limitation unless stockholder approval is obtained, and were classified as liabilities. The issuance increases potential dilution and creates fair-value volatility.
- The company disclosed material weaknesses in internal control over financial reporting, including insufficient expertise for complex accounting, period-end expense accrual and contractor review controls, and review of certain financial calculations. Remediation efforts were underway but the weaknesses were not remediated as of March 31, 2024. Management nevertheless stated that the financial statements fairly present the company’s position and results in all material respects.
- The company reported no material legal matters known to it and no material changes to the risk factors in its 2023 Form 10-K. Development, regulatory, financing, manufacturing, competition, and intellectual-property risks remain relevant; clinical success and timing are uncertain.
Important facts for investors to verify
- Whether Elicio secures financing sufficient to extend runway beyond management’s Q3 2024 estimate, and the resulting terms and dilution.
- Clinical progress, cost, timing, and results for ELI-002 Phase 2 and development plans for ELI-007 and ELI-008.
- Pre-funded warrant settlement terms, any required stockholder approval, the reported warrant liability, and potential share-count impact.
- Progress in remediating the disclosed material weaknesses and the reliability of financial reporting controls.
- Actual operating cash use versus plan, including the timing of clinical spending and changes in payables and accrued expenses.